Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC — Stella

Home/Neuroendocrine Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Neuroendocrine Carcinoma trials

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality

Key details

Sponsor

Fudan University

Enrollment target

~50 participants

Started

January 2021

Primary completion

December 2027

Age range

18 Years and older

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.